Traders should anticipate near-term downward pressure on the stock due to significant dilution. The effective issuance price of ~$0.60 sets a price ceiling; monitor for insider selling or further conversions under the remaining $7.3M note facility.
Price Chart
Executive Summary
Clearmind Medicine Inc. (CMND) announced the conversion of $2,680,029.60 in convertible promissory notes into 4,466,716 common shares on April 21, 2026. This follows a prior agreement to issue notes worth up to $2.7 million at a 10% discount, part of a broader $10 million financing facility. The share issuance results in significant dilution for existing shareholders.
Key Facts
- On April 21, 2026, CLA Investors converted $2,680,029.60 of promissory notes into 4,466,716 common shares
- The conversion implies an effective share price of approximately $0.60 per share
- The shares were issued under a $10 million convertible note facility established in September 2025
- The company previously sold $2.7 million in notes at 90% of face value ($2.43 million in cash proceeds)
- Market cap is only $2 million, making the new share issuance highly dilutive
Financial Impact
Approximately 4.5 million new shares issued at $0.60 effective price, representing substantial dilution given the $2M market cap. The $2.7M note issuance was at a 10% discount to par.
Risk Factors
- Severe shareholder dilution given the small market cap
- Downward pressure on share price due to low conversion price
- Potential for additional conversions under the $10M note facility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-045863 |
| Document: 0001213900-26-045863-index-headers.html | 0001213900-26-045863 |
| Document: 0001213900-26-045863-index.html | 0001213900-26-045863 |
| Document: 0001213900-26-045863.txt | 0001213900-26-045863 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers